Immunohistochemical Evaluation of Cyclin D1 in Breast Cancer

Bilalović, Nurija; Vranić, Semir; Bašić, Hiba; Tatarević, Aida; Selak, Ivan
June 2005
Croatian Medical Journal;2005, Vol. 46 Issue 3, p382
Academic Journal
Aim To explore the potential prognostic value of cyclin D1 in invasive breast cancer and its correlation with basic histopathological parameters, hormonal status (estrogen [ER] and progesterone receptor [PR]), and bcl-2. Methods Medical records of 48 patients, diagnosed in 1998, from the Central Database of the Institute of Oncology, Clinical Center University of Sarajevo, were analyzed. The mean follow-up was 61 months (range: 4-103 months). Routine histopathological evaluation was performed for 48 formalin-fixed and paraffin-embedded tissue samples. For immunohistochemical staining, we used monoclonal antibodies for ER, PR, bcl-2, and cyclin D1. Results Cyclin D1 expression inversely correlated with tumor grade (P = 0.010) and tumor size (P = 0.023), whereas significant positive association was found with ER (P = 0.001) and bcl-2 (P = 0.001) expression. Patients with higher cyclin D1 expression had longer both overall survival (P = 0.014) and relapse-free survival (P = 0.037). Cox regression analysis for overall survival (OS) showed that lymph node status, ER expression, therapy, and cyclin D1 expression were independent prognostic factors. (P range from 0.003 to 0.04). Conclusion Expression of cyclin D1 is associated with better disease outcome in breast cancer.


Related Articles

  • Association of CDKN1B gene polymorphisms with susceptibility to breast cancer: a meta-analysis. Xiang, Heping; Li, He; Ge, Weiwei; Wu, Weidong; Gao, Ming; Wang, Wei; Hong, Lei; Jiang, Datong; Zhang, Changle // Molecular Biology Reports;Nov2013, Vol. 40 Issue 11, p6371 

    A number of case-control studies have been conducted to investigate the association of CDKN1B gene polymorphisms with breast cancer. However, these studies reported conflicting results. The aim of our study was to quantitatively summarize the association of CDKN1B gene polymorphisms with breast...

  • Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Shibata, Masa-Aki; Yoshidome, Katsuhide; Shibata, Eiko; Jorcyk, Cheryl L; Green, Jeffrey E // Cancer Gene Therapy;Jan2001, Vol. 8 Issue 1, p23 

    Mammary carcinomas that develop in C3(1)/SV40 T-antigen (TAg) transgenic mice have lost the p53-mediated induction of p21, leading to increased cellular proliferation and significant elevations of cyclins and Cdks. To test whether p21 could serve as a target for anticancer therapy for this...

  • Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Basso, Andrea D.; Solit, David B.; Munster, Pamela N.; Rosen, Neal // Oncogene;2/14/2002, Vol. 21 Issue 8, p1159 

    Presents a study that examined the function of Akt activation by HER2/HER3 heterodimers in D-cyclin expression for breast cancers with high HER2. Background on ansamycin antibiotics; Causes of the downregulation of D-cyclin; Impact of 17-AAG on the phosphorylation of Akt; Characteristics of...

  • CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. Iorns, Elizabeth; Martens-de Kemp, Sanne R.; Lord, Christopher J.; Ashworth, Alan // Carcinogenesis;Oct2009, Vol. 30 Issue 10, p1696 

    Endocrine therapies, which inhibit estrogen receptor (ER)α signaling, are the most common and effective treatment for ERα-positive breast cancer. However, the use of these agents is limited by the frequent development of resistance. The cyclin-dependent kinase family member CRK7 (aka...

  • CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Somaia Elsheikh; Andrew Green; Mohammed Aleskandarany; Matthew Grainge; Claire Paish; Maryou Lambros; Jorge Reis-Filho; Ian Ellis // Breast Cancer Research & Treatment;May2008, Vol. 109 Issue 2, p325 

    Abstract Introduction  Despite strong evidence regarding the role of CCND1 amplification and protein overexpression in breast carcinoma, the associations between CCND1 amplification/cyclin D1 overexpression and clinicopathological variables and clinical outcome remain controversial. ...

  • Are all cancer genes equal? Bartek, Jiri; Lukas, Jiri // Nature;6/28/2001, Vol. 411 Issue 6841, p1001 

    Focuses on a study about the effect of removing cyclin D1 protein on breast cancer, based on a study conducted by Yu and colleagues. Behavior of cancerous mammalian cells; Information on cyclins; Conclusion of the study.

  • A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Dickson, Mark A.; Shah, Manish A.; Rathkopf, Dana; Tse, Archie; Carvajal, Richard D.; Nian Wu; Lefkowitz, Robert A.; Gonen, Mithat; Cane, Lauren M.; Dials, Heather J.; Schwartz, Gary K. // Cancer Chemotherapy & Pharmacology;Nov2010, Vol. 66 Issue 6, p1113 

    Background: The cyclin-dependent kinase inhibitor flavopiridol increases irinotecan- and fluorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + flavopiridol in patients with advanced solid tumors. Design: FOLFIRI + flavopiridol were administered every 2 weeks. Based on...

  • Protein microarrays identify antibodies to protein kinase Cζ that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Sutherland, Scott M.; Li Li; Sigdel, Tara K.; Wadia, Persis P.; Miklos, David B.; Butte, Atul J.; Sarwal, Minnie M. // Kidney International;Dec2009, Vol. 76 Issue 12, p1277 

    Antibodies to human leukocyte antigens (HLAs) are a risk factor for acute renal allograft rejection and loss. The role of non-HLAs and their significance to allograft rejection have gained recent attention. Here, we applied protein microarray technology, with the capacity to simultaneously...

  • Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell growth arrest and p27Kip1 induction. Xiaoduo Xie; Zhenzhen Wang; Yan Chen // Molecular & Cellular Biochemistry;Jul2007, Vol. 301 Issue 1/2, p115 

    Abstract  Germline mutations of the serine/threonine kinase LKB1 (also known as STK11) lead to Peutz–Jeghers syndrome (PJS) that is associated with increased incidence of malignant cancers. However, the tumor suppressor function of LKB1 has not been fully elucidated. We applied...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics